| 27.91 -0.24 (-0.85%) | 09-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 36.83  |
1-year : | 39.64 |
| Resists | First : | 31.54 |
Second : | 33.93 |
| Pivot price | 30.24 |
|||
| Supports | First : | 27.65 |
Second : | 23.01 |
| MAs | MA(5) : | 28.8 |
MA(20) : | 30.8 |
| MA(100) : | 30.96 |
MA(250) : | 31.15  |
|
| MACD | MACD : | -0.8 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 7.4 |
D(3) : | 7.1 |
| RSI | RSI(14): 32.7 |
|||
| 52-week | High : | 40.22 | Low : | 20.31 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ STOK ] has closed above bottom band by 8.6%. Bollinger Bands are 24.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 28.65 - 28.81 | 28.81 - 28.99 |
| Low: | 27.21 - 27.39 | 27.39 - 27.58 |
| Close: | 27.57 - 27.88 | 27.88 - 28.22 |
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.
Wed, 16 Sep 2026
Stoke Therapeutics, Inc. (STOK) Stock Price, News, Quote & History - Yahoo Finance
Wed, 16 Sep 2026
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
Tue, 08 Sep 2026
Legal & General Group Plc Makes New Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat
Thu, 03 Sep 2026
The Manufacturers Life Insurance Company Makes New Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat
Thu, 03 Sep 2026
Stoke Therapeutics (STOK) CMO sells 5,545 shares under pre-set plan - Stock Titan
Wed, 02 Sep 2026
Stoke Therapeutics, Inc. $STOK Shares Acquired by Wellington Management Group LLP - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 65 (M) |
| Shares Float | 49 (M) |
| Held by Insiders | 3.6 (%) |
| Held by Institutions | 123.6 (%) |
| Shares Short | 12,980 (K) |
| Shares Short P.Month | 15,690 (K) |
| EPS | -3.4 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.53 |
| Profit Margin | 0 % |
| Operating Margin | -701.7 % |
| Return on Assets (ttm) | -35.9 % |
| Return on Equity (ttm) | -61.1 % |
| Qtrly Rev. Growth | -32.5 % |
| Gross Profit (p.s.) | 0.42 |
| Sales Per Share | 0.42 |
| EBITDA (p.s.) | -3.44 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -178 (M) |
| Levered Free Cash Flow | -106 (M) |
| PE Ratio | -8.24 |
| PEG Ratio | 0 |
| Price to Book value | 5.03 |
| Price to Sales | 65.27 |
| Price to Cash Flow | -10.12 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|